GenFleet Doses First Patients in China, Australia in GFH276 Combination Trial for Pancreatic Cancer
- GenFleet Therapeutics announced initial dosing in China and Australia for its Phase Ib/II GFH276 combination trial on Nov. 16, 2026.
- The study will assess the oral pan-RAS inhibitor’s safety and efficacy in patients with RAS-mutant pancreatic cancer and solid tumors.
- Phase II will evaluate three first-line pancreatic cancer combinations: GFH276 with cetuximab, AG chemotherapy or mFOLFIRINOX chemotherapy.
- Monotherapy results already presented at this year’s ESMO meeting showed tumor responses in previously treated pancreatic cancer, with no dose-limiting toxicities observed.
- Preclinical findings already presented at this year’s AACR meeting showed enhanced antitumor activity when GFH276 was combined with standard treatments.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genfleet Therapeutics (Shanghai) Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261116-12413149), on November 16, 2026, and is solely responsible for the information contained therein.